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Abstract: The significant development in the construction of microscale cell culture platforms and the interest in
bioanalytical analysis have recently resulted in the emergence of a new concept of ‘organ-on-a-chip’ systems. Organon-a-chip is a new three-dimensional (3D) in vitro microfabricated unit that contains a multichannel microfluidic cell
culture. Even if many informative and useful data are obtained from animal models and in vitro assays, they are still
limited for extrapolation to human systems during drug design and development. Only about 1 out of 10,000 compounds
is processed in clinical trials for final approval. As being the first example of its kind, in this review, we summarize the
current status and future challenges of this new concept that is a promising radical improvement in the drug-monitoring
field. In addition, 3D-bioprinting methods used for the construction of organs-on-chips are outlined within the context
in order to address the complexities in the field and show the various ways to create these semiartificial hybrid devices
using a multidisciplinary approach comprising chemistry, biology, and engineering.
Key words: Organ-on-a-chip, 3D bioprinting, drug screening, in vitro cell culture

1. Introduction
It is well known that the determination of the absorption, distribution, metabolism, and elimination of a drug
in the human body is a very complex process and needs highly sophisticated methods and tools. 1−7 During
these processes, the investigation of a correlation between concentration and time of the initial-loaded drug in
the bloodstream and in the tissues of organs is very crucial to understand the interaction and the eﬀects of
the drug in the body. An important approach toward these interaction profiles is using and analyzing some
mathematical models. For example, Shuler 8 developed a pharmacokinetic–pharmacodynamic (PK-PD) model
to correlate data obtained from organs-on-chips with the data from in vivo experiments. In addition, Sung et al.
combined PK-PD modeling with a microscale cell culture analog, which is an in vitro experimental approach, to
comprehend the mechanism of drug toxicity. 6 Bhise et al. suggested that computational fluid dynamics models
can provide a mechanistic understanding of drug delivery in organ-on-a-chip systems. 9
Cost and time are two important parameters for investigating and developing new drugs. It takes about
12 to 15 years to develop a new drug, and only a few of these drugs are approved by the authorities. 7 Various
reasons for failure in drug development attempts are directly related to the lack of eﬃcacy and their severe side
eﬀects, which could not be observed by current in vivo and in vitro models. 5,7 In vitro cell or tissue culture
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models can give the first indication of the eﬃcacy and toxicity of the drug for physiological and pathological
responses. 5 If in vitro results are promising, the eﬀect of the compound can be investigated by using animal
models. However, these two models have crucial shortcomings. For example, in vitro models do not represent
complex cell–cell and cell–matrix interactions, which may result in inaccurate diagnostic bias. 5 Some candidate
compounds can be eﬀective in vitro but ineﬀective in vivo because of the complex interactions between the
drug and the biological environment, especially in cells and tissues. The unforeseen lack of eﬃcacy or toxicity,
which is not revealed in vitro studies, is one of the important reasons for the high attrition rate. Therefore, a
very high rate of failure and expenses associated with the drug development research occur in the later clinical
investigations of phases II and III. 6,7
Therefore, it is important to conduct appropriate and precise experiments before the clinical trials that can
also help to reduce cost and time tremendously. In order to solve this problem, the ‘organ-on-a-chip’ concept
has been developed as an alternative in vitro technique. Organs-on-chips closely mimic human tissues and
organs by using multichannel 3D microfluidic and other microfabricated structures that give the opportunity to
observe the activities, mechanics, and physiological responses as observed for human organs. 4,5,10 It is believed
that experimentation with animal testing could soon be replaced by some of these sophisticated organ-on-achip models. It is also foreseen that this would pave the way forward for the development of inexpensive and fast
testing of potentially new diagnostic and therapeutic approaches. In this technology, the microstructures behave
as scaﬀolding for the growth of human cells and provide an interaction between the cells and the molecules such
as drug particles and ions.
Recent technological advancements have been invaluable to understand the functioning of artificial organs
(i.e. heart, kidneys, liver, lung, and vessels). This in vitro progress has enabled cellular environments closely
mimicking the properties of human tissues and organs in many aspects. The next achievement was the
integration of these artificial microengineered tissues and organs with stem cell technology to obtain ‘bodyor human-on-a-chip’ systems and to observe the eﬀects of drugs on the human body during the proposed
treatment period. The use of such systems will considerably reduce the time and cost of the development of
novel drugs and associated treatment in the pharmaceutical and medical industries. 5,11,12
In this review, briefly, recent advances in in vitro tissue culture models, organ-on-a-chip platforms, and
their physiological relevance are presented. The review also provides exclusive information about the current
and future challenges. The final section is dedicated to the various 3D bioprinting technologies used in the field
so that a complete understanding of the subject is reached.
2. Recent developments in organ-on-chip technologies
In this section, specific examples of the latest research eﬀorts for mimicking the kidneys, lungs, heart, blood
vessels, and liver are outlined to demonstrate the use of these platforms. Furthermore, as a new and promising
technology for tissue model development, recent 3D bioprinting technologies are highlighted in the next section.
Material, mathematical, and physical simulation necessities in order to advance organ-on-a-chip technologies
and finally the significant advantages are mentioned in Section 4.
2.1. Kidney-on-a-chip
The kidney is one of the most complicated organs in the human body; therefore, it is an enormous challenge
for researchers to develop a platform of ‘kidney-on-a-chip’ that can mimic its function partially or fully when
exposed to various drugs and medications.
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The nephron is the functional and basic structural unit of the kidney. It regulates the concentration
of water and soluble substances during filtering of our blood, and the desired substances for our body are
reabsorbed while excreting the remaining ones as urine. 11 A nephron can be divided into three main sections,
in which the blood first enters the glomerulus, where the passive mechanical filtration occurs to hold the cells
and large proteins. In the second section, the blood and filtrate flow reach the proximal tubule where the
reabsorption process takes place. The filtration process is completed in the loop of Henle by osmosis, diﬀusion,
and reabsorption. The filtrate is eventually transferred to the collecting duct system after passing through
the distal convoluted tubule, responsible for the regulations of ions and pH, and is processed there to form
concentrated waste urine. 13
An on-chip nephron device made out of a single multilayered polymer construct has been proposed by
Weinberg et al. 14 The chip resembles the functioning nephron with these three sections, namely the glomerulus,
the proximal tubule, and the loop of Henle, as shown in Figure 1. It is made up of two microfabricated layers
separated by a membrane. The filtration of the glomerular unit, the reabsorption in the tubule, and the large
increase in urea concentration in the loop of Henle were all observed when a blood sample was introduced
into the on-chip nephron device. This was one of the first attempts in the field. Though it was a successful
attempt, there were challenges to be addressed related to the culture and control of the various cell types, and
the filtration process for the separation of waste was not as eﬃcient as for the normal nephron.

Figure 1. Schematic representation of the nephron device (reprinted with permission from Weinberg et al.; copyright
(2008), Wichtig Publishing 14 ) .

Jang et al. developed a polydimethyl siloxane (PDMS)-based microfluidic device with a porous membrane
substrate sandwiched in the middle. 13 It was designed to proliferate and investigate renal cells of the tubule of
the kidney, as shown in Figure 2. In this model, primary rat inner medullary collecting duct (IMCD) cells were
cultured in the microfluidic channels, and the optimum environmental conditions for the cells were obtained
by the application of an appropriate fluidic shear stress for a certain time. Under these conditions of fluidic
shear stress, the cultured IMCD cells exhibited improved alignment of the cytoskeleton, cell polarization, cell
junctions, and hormonal stimulations initiated regulating water and ion balance by molecular transport when
compared with the same cell type cultured statically.
Another research group recently reported an alternative version of the chip in order to construct ‘in
vivo-like’ proximal tubular morphology for the study of renal toxicity. 15 Their work is the first of its kind that
uses primary human kidney proximal tubular epithelial cells in a microfluidic device exploring nephrotoxicity
under dynamic fluidic flow. A PDMS-based microfluidic device is separated by a porous (pore size: 0.4 mm)
polyester membrane, as seen in Figure 3. This structure closely resembles the flow mechanism of the tubular
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Figure 2. Schematic of the MMD device: (a) assembly of the device by plasma treatment; (b) working principle of
the MMD device on a culture dish that has a syringe pump with silicone tubes; (c) schematic of the functional device;
(d) a microscope image of primary cultured rat IMCD cells within the inside channel of MMD after seeding for 3 days
(reprinted with permission from Jang et al.; copyright (2010), The Royal Society of Chemistry 13 ) .

flow of interstitial fluid at the tissue–tissue interface of the kidney proximal tubule. The upper surface of
the extracellular matrix (ECM)-coated membrane was seeded and spread by the epithelial cells, and then the
compartment was filled with the culture medium, flowing with a low level of shear stress. The lower section of
the device was loaded with the culture medium in order to form a similar environment for the interstitial space
of the kidney.

Figure 3.

Microdevice engineering of human kidney proximal tubule-on-a-chip: (A) schematic representation of

intraluminal channel and interstitial space, which is divided by an ECM-coated porous membrane. Human proximal
tubule epithelial cells are plated on the porous membrane active and passive epithelial transport similar to the living
kidney proximal tubule. (B) Schematic of the device assembly; top microfluidic channel, ECM-coated porous membrane,
and lower microfluidic channel combined together by the treatment of surface plasma. Cells are placed through device
inlet. Inlets show the structure of the tubular flow in nephron (reprinted with permission from Jang et al.; copyright
(2013), The Royal Society of Chemistry 15 ) .
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The number of cells expressing primary cilia was also tremendously increased when they were exposed by
the apical shear stress. It is known that the primary cilia are one of the essential parts for fluid mechanosensing
and regulation of tubular morphology. Another interesting use of the device was the ability to determine the
physiological transport functions by observing the albumin uptake rate from the apical medium under static
and fluidic conditions. Under appropriate fluidic conditions, the albumin uptake percent could be improved
by more than double, making the device an in vivo-like phenotype. Toxicity tests were also carried out by
injecting cisplatin, which is a chemotherapeutic drug, into the interstitial part of the microdevice to observe
the eﬀects of conditions in terms of cell injury as determined by lactate dehydrogenase release. The presence of
flow significantly improved the response of the toxicity of the cells; they were healthier when compared with the
cells cultured under static conditions. As a result, this microdevice model can give more accurate information
for those working on kidney diseases and nephrotoxicity, as well. Furthermore, it is important to mention that
this model is one of the first to use primary human kidney proximal tubular epithelial cells to compare the
transport activities between static and fluidic culture environments.
A 3D bioprinting of convoluted proximal tubules was shown in a recent work. 16 Here, the proximal
tubule construct was fabricated using a 3D bioprinter. This method provides enhanced epithelial morphology
and functional properties compared to 2D constructs. Additionally, the same methodology can be applied to
produce other parts of the nephron, such as the distal convoluted tubule or loop of Henle.

2.2. Lung-on-a-chip
The lung is the primary organ in the respiratory system. In the normal human respiratory system, the trachea
transfers the inhaled air into the lungs through the tubular branches, also called bronchi. Bronchi are divided
into smaller branches ending with the alveoli, where the exchange of gases occurs. Oxygen passes from the
air into the blood, and similarly carbon dioxide passes from the bloodstream into the atmosphere through
the alveoli. Alveoli are covered with capillaries carrying the blood plasma. The membrane at the interface
between alveoli and capillaries consists of epithelial cells from the alveoli side and endothelial cells from the
capillary side. 11 The human airway epitheliums (e.g., ciliated, mucous, type I and type II cells in the alveolar
epithelium) have unique physicochemical and immune barriers between the host and the environment and are
able to respond to a wide range of outcomes. 17−19 For example, the interaction of a receptor (Fas (CD95))
and its ligand (FasL) in the airway epithelium can act as an immune barrier in which the apoptosis of cells is
initiated.
Studying lungs-on-microchips can oﬀer a new pathway in order to analyze airborne diseases and to screen
therapeutic eﬀects of the associated drugs. It is important because of the considerable increase in air pollution,
especially in developing countries, and the eventual increase in lung-associated illnesses. One of the first
‘lungs-on-chips’ was designed with inspiration from human breathing. 20 It was formed by two closely apposed
microchannels separated by a flexible, porous, and very thin (10 µ m) membrane manufactured from PDMS. The
membrane in between was coated with ECM (consisting of fibronectin or collagen). The schematic of the device
is shown in Figure 4. Human alveolar epithelial cells and human pulmonary microvascular endothelial cells
were cultured on the opposite sides of the membrane. The air was introduced into the epithelial compartment,
while the bottom microchannel filled with endothelial cells was infused with a blood-like liquid. A vacuum
was applied to the microchambers to enable mechanical stretching of the PDMS membrane mimicking human
breathing. The proposed system delivers the fluid flow well, distributing cells and nutrients to the epithelium
and endothelium. In addition to the study of alveolar epithelial and endothelial cells, they used immune cells in
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order to obtain similar human lung responses to infection and inflammation triggered by inhaled pathogens. It
is clear that the chip demonstrates a low-cost screening model that could potentially replace currently available
in vivo assays.

Figure 4. Schematic representation of a lung-on-a-chip microdevice: (A) schematic of the device: device consists of
PDMS microchannels with ECM-coated porous and flexible PDMS membrane representing an alveolar-capillary barrier.
Vacuum is applied to the side chambers to obtain mechanical stretching to mimic the alveolar-capillary barrier. (B)
Schematic of the lung working principles: upon inhalation intrapleural pressure decreases while the alveolar-capillary
interface stretches due to the tension of the alveoli. (C) Device construction: upper and bottom microchannels with
a membrane in between are bonded together with plasma exposure. (D) PDMS etchant is used in the side chambers
to remove the membrane for vacuum applications. (E) Photography images of lung-on-a-chip microdevice. Scale bar:
200 µ m (reprinted with permission from Huh et al.; copyright (2010), American Association for the Advancement of
Science 20 ) .

Another group of researchers produced a lung-on-a-chip microdevice to improve the physiological relevance of existing in vitro alveolar capillary interface models. 21 They successfully cultured alveolar epithelial cells
at an air–liquid interface with continuous nutrient perfusion and this also showed a higher degree of monolayer
integrity and a decrease in surface tension of the hypophase. The production steps of a multilayer microfluidic
cell-culture device are shown Figure 5 in detail. In general, porous polyethylene terephthalate (PET) membrane
(pore size: 0.4 mm) was sandwiched between the bottom and the top layer of PDMS in the microdevice. Afterwards, a mixed liquid of PDMS as a curing agent for the prepolymer was used to bond the layers together,
followed by a final curing step under a suitable heating process. The human alveolar epithelial cells were placed
on the top and bottom of the PET culture wells of the device.
To determine the cell monolayer integrity under diﬀerent culture conditions (i.e. atmospheric air, culture
media) transepithelial electrical resistance (TEER) measurements were carried out, and it was found that the
cells indicated tight junctions under both conditions. However, the air-exposed cultures demonstrated higher
TEER values than the cells cultured in media. In addition to TEER observations, sodium fluorescein uptake
for permeability studies was investigated under the two abovementioned culture conditions. Reduction in
permeability was higher for air-exposed cells than that for the cultured cells. This indicated better cell viability
and monolayer integrity for the air-exposed cultures.
Use of such a device brings the advantages of good integrity of closely packed cells, eﬃcient waste removal
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Figure 5. (a) Illustration of production steps for the microfluidic device: (i) preparing for the formation of a lightsensitive film used for photolithography (SU-8) on silicon wafer; (ii) the curing process of liquid PDMS with 1:10 ratio of
curing agent to prepolymer mix on the SU-8 substrate for 30 min at 80

◦

C; (iii) negative relief structure in PDMS slab

to obtain small holes; (iv) placing the access ports in the PDMS mold; (v) formation of the culture wells; (vi) assembling
the device by bonding the bottom PDMS layer to a glass slide via exposure of O 2 plasma for 2 min at 25 W and then
heating at 80

◦

C for 1 h; (vii) final device structure with fluidic connections to the lower PDMS layer and cell culture.

(b) Images of an actual and a schematic display of the multilayer microfluidic cell-culture device with the cross-sectional
view of red dotted line that shows suspended PET membranes supporting alveolar cells (reprinted with permission from
Nalayanda et al.; copyright (2009), Springer International Publishing 21 ) .

and constant nutrient replenishment, and a lower surface tension of the hypophase with the consistently higher
presence of surfactant during cell growth. In addition, the device is an open-access model where one can study
diﬀerent cell culture models, drugs, and treatment systems experiencing dynamic forces. All of the above make
this model a promising tool imitating the physiological environment of the lung similarly to the real one.
2.3. Heart-on-a-chip
The cardiovascular system has a crucial function in the human body, consisting of the heart, blood, blood
vessels, and lymphatic system. They are mainly responsible for the transport of O 2 , CO 2 , nutrients, cellular
waste, and hormones throughout the body. The heart is a vital part of the cardiovascular system and is the
body’s hardest working organ due to working for the entire life without stopping to pump the blood throughout
the entire body. It is located more to the left of the breastbone in the middle mediastinum and connects to
the largest artery, the aorta, in the human body. The heart manages many sensitive processes in the body very
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well; for example, it controls the synchronized contraction of the individual myocytes (also known as muscle
cells) in a certain period of time and the opening of the valves without any leak. During diastole, the ventricles
are filled with blood properly, and the degree of contractions is suﬃciently adequate. 22 The heart includes
permanent cells, such as cardiomyocytes, cardiac fibroblasts, and endothelial cells, and transient cell groups,
which include lymphocytes, mast cells, and macrophages. 11 These two groups of permanent and transient cells
have interactions between each other and these interactions influence the function of the cardiac system.
In the past, in general, the correlation between electrophysiological and contractility properties of cardiac
cells was observed from a single cardiomyocyte. It is clear that the cultures of cardiac myocytes do not give
the whole response and the structure of the cardiac tissue, and some functions should be protected, such as
contractility and the ion channel composition of the original cells. 23 In addition, to obtain more accurate
data, there should be at least a single or multiple tissue scale systems. Grosberg et al. reported obtaining a
‘heart-on-a-chip’ based on a muscular thin film (MTF) technique that comprised a ventricular myocardium on an
elastomeric thin film. 24 The contractility for up to eight MTFs and cytoskeletal construction for multiple tissues
were achievable. Therefore, it is a significant example providing the relation between structure and function
and simulating the architecture of laminar cardiac muscle. In this study, after the production of the MTF
chips, the surface was spin-coated with poly(N-isopropylacrylamide) (PIPAAm) and later coated by PDMS, as
shown in Figure 6. An ECM protein, fibronectin, was utilized to provide guidance cues for self-assembly of
myocytes. The myocytes were then seeded on the substrates and cultured for a certain time prior to conducting
the experiments.
An external field stimulator with a digital video was used in order to analyze each contraction cycle
and monitor the systolic and diastolic stresses. In addition, diﬀerent concentrations of a dose of epinephrine,
electrophysiological mapping, and immunofluorescent staining (e.g., actin, nuclei) were studied to analyze
pharmacological responses. As a result, one can say that this chip technology with various cell-culturing
models has shown an investigation of stress and electrophysiological activity. It also well resembles the cellular
architecture in healthy, diseased, and developing cardiac tissues.
Another novel engineered heart prototype was reported by Agarwal et al. 25 Their work showed a laserinduced fabrication of thin PDMS cantilevers. Some advantages of this MTF technology over conventional ones
can be summarized as mimicking the similar response of in vivo physiology, contractility, and electrophysiological
properties. The use of autoclavable materials was also a plus here, which prevented the absorption of drug
molecules during the in vitro drug treatment. It should be noted that the team obtained similar data of
average peak systolic and twitch stress for each MTF after each contraction until four cycles (Figure 7) in
MTF experiments, which were isolated rat papillary muscle contractility experiments performed in an openwell configuration. Furthermore, the higher reproducibility rate of the MTF technology, the opportunity to work
with diﬀerent types of cell sources (i.e. primary human cardiomyocytes), and the simultaneous observation of
multiple tissue responses for the study of contractility properties under diﬀerent exposure regimes during the
treatment with and without drugs were some other advantages of the device. This was also one of the first
designs that would potentially enable the mimicking of diseased organs by the perfusion of suitable target
molecules.
Mechanical and biological properties of cardiac muscle cells such as alignment, elongation, and growth
properties should be considered when designing artificial cardiac tissue. In this regard, there are also some
important studies showing the production and analysis of hydrogel-based microarchitecture designs for probing
the structure and functional properties of actual cardiac tissue under physiological conditions. 26−29 Hydrogels
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Figure 6. Schematic of systematic fabrication of heart-on-a-chip: (a) production of single 25-mm-wide round template;
(b) batch production of the templates; (c) contractility assay development: neonatal rat ventricular myocytes are seeded
on the surface of the functionalized substrate. Bottom row shows the 3D schematic representation, top row is the top
view of the design, and left is voltage-sensitive dye for membrane dye staining (staining agent used in immunostaining
for α -actinin – red, actin – green, nuclei – blue (right image)). Scale bar is 20 µ m (reprinted with permission from
Grosberg et al.; copyright (2011), The Royal Society of Chemistry 24 ) .

demonstrate a microstructure very similar to the native ECMs with tunable mechanical properties like allowing
transport of nutrients, wastes, and high oxygen content. Among the controllable features, the properties of
hydrogels are those to provide biological communication for cells, biodegradability, and ease for the transport
of solutes. Consequently, synthesis of hydrogels with various chemical and physical properties for regenerative
medicine, tissue engineering, and biomimetic tissue construction applications has been increasing rapidly. 28
Furthermore, many published studies related to direct and indirect patterning to precisely control the spatial
position of the cells within the hydrogel only barely achieved the spatial location and proper control over the cell
density. More recently, Naseer et al. demonstrated an acoustic-based technique called surface acoustic waves
(SAWs) to pattern the cardiac cells in a quick, controllable, and contactless fashion within gelatin methacryloyl
(GelMA). 29 The standing SAW-induced energy transferred into the gel was used to position and align the cells
less than 10 s before photo-crosslinking the chains of GelMA. They successfully observed beating activity less
than a week after the cell alignment and spreading.
Annabi et al. developed functional cardiac tissue models via photo-crosslinking of methacrylated tropoelastin (MeTro) in order to mimic its dynamic properties. 30 They also studied the behavior of cardiomyocyte
attachment, alignment, spreading, and communication. For these novel engineered micropatterned elastic gels,
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Figure 7. Images and graph for the proposed heart-on-a-chip design: (a) bright-field image for the performance of the
chip during diastole and (b) peak systole with scale bar of 1 mm; (c) and (d) show the higher magnification of (a) and
(b) with scale bar of 1 mm; (e) graph showing diastolic, peak systolic, and twitch stress response for each MTF design
(e.g., an average twitch stress after 35 replicates is 12.7 ± 1.1 kPa by using one higher-throughput chip); (f) fluorescent
image for immunostaining of the actin filaments and nuclei (represent by red and blue, respectively); (g) represents the
region highlighted as a yellow rectangle in (c) and demonstrates sarcomeric α -actinin for the generation of an anisotropic
monolayer for the cardiac tissue (reprinted with permission from Agarwal et al.; copyright (2013), The Royal Society of
Chemistry 25 ) .

a human protein of water-soluble tropoelastin, which consists of 35 lysine residues per molecule, was used in
the formation of highly elastic MeTro gel. This gel also has high-resolution microchannels on the surface, as
seen in Figure 8. Higher elongation at break up to 400% and tensile modulus of about 15 kPa, which is close
to the modulus of rat CMs of 30 kPa, were some important results produced using MeTro hydrogel. In fact,
UV exposure times, the components’ concentrations in MeTro gel, channel width, and culture time should be
carefully controlled and optimized to obtain well-defined microscale structures mimicking the native rat heart.
After CM attachment on MeTro hydrogel, a higher rate of cell proliferation, an anisotropic arrangement with
suﬃcient spreading ability, and a confluent cell layer elongation were observed. In terms of the immunohistochemical detection capability of the gel, it can be seen that a well-defined sarcomere structure forms a formation
similar to the ventricular myocardium of a native adult rat. Additionally, there was not any significant change
in the beat frequency across the culture time; a consistently synchronized beating of systole and diastole could
be maintained at least 2 weeks in response to optimized electrical field stimulation. It would be conceivable
to think that further development of the system, which also includes intercalated disk and gap junctions between myocytes with higher alignment and elongation of cardiac troponin I (cTnI), would potentially lead to it
resembling the native myocardium more.
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Figure 8. Illustrations of production process for patterned PDMS molds, MeTro gel, and cardiomyocyte alignment and
attachment on the gels: (a) producing patterned PDMS molds; (b) manufacturing micropatterned MeTro gel by placing
the molds in MeTro and photoinitiator solution placed on a glass slide, UV light exposure for crosslinking, and then the
PDMS removal; (c) cell alignment and attachment on unpatterned and patterned gels by seeding cardiomyocytes isolated
from neonatal rats for the cell alignment and attachment (reprinted with permission from Annabi et al.; copyright (2013),
John Wiley & Sons 30 ) .

2.4. Vessel-on-a-chip
Blood vessels are one of the most important parts of the circulatory system for mammals in particular, which
have a closed blood vascular system. In general, blood vessels are of three diﬀerent types: arteries, which
conduct the blood from the heart to the various tissues and organs; veins, which carry blood from tissues
and organs to the heart; and finally capillaries, in which the actual exchange of water, chemicals, oxygen, and
carbon dioxide takes place between the blood and the tissue fluid. The structure of blood vessels contains three
layers, and these are mainly called ‘tunica’. 31 The name of the outermost layer is tunica adventitia or tunica
external; it is the thickest layer in veins and contains some elastic fibers, mostly collagen, with infiltrated nerve
fibers. The tunica media is the middle layer and the thickest layer in arteries that is formed of mainly circularly
arranged elastic smooth muscle cells and elastic and collagen fibers. The innermost layer is the thinnest part
and named tunica intima, composed of a single layer of simple flattened endothelial cells that are surrounded by
subendothelial connective tissue with collagen fiber and smooth muscle cells. Endothelial and smooth muscle
cells are important structure parameters of the vessel wall, which also has a crucial role in the pathogenesis of
many diseases. A schematic diagram describing a typical artery is shown in Figure 9. 32
Vascular grafts are used in order to treat damaged, occluded, and diseased arteries. They can have
diﬀerent diameters ranging from millimeters to centimeters with diﬀerent material types and forms. The
compliance (the fractional increase in diameter) and the vascular patency (the condition of being blocked,
obstructed or not) are two important parameters for vascular grafts. Some of these values for various vessels
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Figure 9. Schematic diagram describing a typical artery with the tunica external, the tunica media, and the tunica
intima (reprinted with permission from Shankar; copyright (2016), PathologyOutlines.com 32 ) .

are demonstrated in the Table. The compliance and the patency performance of vascular grafts made of Dacron
and PET and their comparison with some other natural arteries and veins are illustrated here. 33
Table. Compliance and patency values for various vessels. 33

Host artery
Saphenous vein
Umbilical vein
Bovine heterograft
Dacron
PTFE

Compliance (% / mmHg × 100)
5.9
4.4
3.7
2.6
1.9
1.6

Patency (%), 1 year
...
88
83
65
65
60

Patency (%), 2 years
...
84
80
59
42
42

Developing microfluidic devices simulating the biological response of the blood vessels will give us the
opportunity for a better comprehensive understanding of the mechanisms behind pathologic changes, responses,
and natural functions. Engineered 3D vascular structures can oﬀer many advantages for cell seeding, culturing,
and analysis. 34 Recently, several studies have described in vitro human and personalized disease models to
develop therapeutic strategies. 35−38 In this regard, a thrombosis-on-chip model using 3D bioprinting technology
has been demonstrated. 35 In this model, Pluronic sacrificial micron-sized channels were formed and then coated
with a layer of human umbilical vein endothelial cells (HUVECs), and then embedded in GelMA hydrogels.
Moreover, in order to mimic human fibrosis and aging, the channels were then coated by fibroblasts whereby
they observed that the cells migrated into the clot and deposited collagen type I when the endothelium was
damaged. Studying the real situation of the pathology of fibrosis, and especially in thrombosis, in such systems
could open up new avenues in medicine.
Additionally, conventional PDMS-based microfluidic channel manufacturing without pretreatment and
further modifications might create some challenges when vascular phenomena are explored for cell functioning
and behavior under fluid flow for the implementation of drug testing. 36 In this respect, Chung et al. developed a microfluidic platform to study cell migration and behavior under physiological conditions of biophysical,
biochemical, and coculture environments. 37 In this study, 3D microenvironments were obtained via soft lithography using PDMS as seen in Figure 10. This model consists of condition (test agents) and control (control
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medium) channels in which observation of cell migration, growth factors, and cell polarity demonstrated significant diﬀerences. For example, cell migration was faster between the center and condition channels than the
control part. However, increasing the collagen gel stiﬀness for cell adhesion inhibited endothelial cell migration,
causing formation of tube-like structures with a diameter of about 20–30 µ m even if the cells in softer scaﬀolds
migrated throughout the entire scaﬀolds. This, in turn, allowed controlling cell behavior by changing the mechanical properties of the scaﬀold. Researchers also studied the behavior of coculturing endothelial cells with
various types of cancer cells that were cultured in the condition channel. This is important since cancer stromal
cells can induce capillary formation, angiogenesis, by signaling endothelial cells. In this study, MTLn3 cancer
cells attracted human microvascular endothelial cells (HMVECs) that were cultured in the cell channel (Figure
10) for the formation of a capillary structure but the low density of cancer cells could not excite tremendous
migration of HMVECs. Furthermore, interactions between vascular smooth muscle cells and endothelial cells,
which were cultured in the condition and the cell channels, respectively, were also studied; there was communication between the cells but migration of the endothelial cells was suppressed by smooth muscle cells on both
sides of channels although they could migrate only on the control side.

Figure 10. Development of the microscale models: (a) soft lithography and surface treatment; (b) production of cell
scaﬀolds in microchannels (brown represents the gel); (c) filling of the media in the microchannels (blue); (d) the seeding
of the cells (spheres) in the central channel; (e) the application of chemical factors (green) in the condition channel;
(f) schematic representation of the whole microfluidic device; (g) operational view of 3D microdevice and cell migration
behaviors (reprinted with permission from Chung et al.; copyright (2009), The Royal Society of Chemistry 37 ) .

In another study, Zheng et al. developed a microfluidic flow-stretch chip in order to obtain better
mimicking of human biology and explore the cardiovascular system by physical stimulations. 38 To do so, the
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eﬀects of fluid shear stress and cyclic stretch created by blood flow and blood pressure on vascular cells and
blood vessels’ microenvironment, respectively, were investigated.
An additional study was conducted by Kaji et al. in order to monitor the interactions between HeLa
cells, a human cervix epithelial cell line, and HUVECs. 39 For this purpose, the group developed a modified
type of microfluidic device, which consists of a detachable substrate-based coculture system with glass plate,
presensitized (PS) plate, and a PDMS layer, as illustrated in Figure 11. Interactions between the cells were
controlled by soluble signaling parameters via coculture of these cell environments. They also developed a
system of bubble trapping for the culture medium in order to prevent the negative eﬀect of air bubbles on the
cells. The flow direction of the medium was reversed from the HeLa to the HUVEC side and from the HUVEC
to the HeLa side. When the HeLa cells were migrated into the areas where HUVECs were already in the space,
the HUVECs retreated faster than the HeLa cells migrated. On the other hand, when the second case was
applied, in which the flow was from the HUVEC to the HeLa side, interestingly there was a short distance of
withdrawal of the HUVECs with a group of the HeLa cells migrating into the HUVECs. There were two groups
of these cells interacting and coming into contact during the period of the culture time. Researchers suggest
that this diﬀerent response was probably due to paracrine signaling. As a result, controlling soluble signaling
factors secreted from the cell types made the observation of tunable cell migrations and behaviors possible.

Figure 11. Representation of vessel-on-a-chip device developed by Kaji et al.: 33 (a) schematic of the chip assembly
(detachable substrate and PDMS layer with glass plate at the top are bonded together upon plasma treatment); (b)
photography image of the assembled device with scale bar of 5 mm (reprinted with permission from Kaji et al.; copyright
(2010), The Royal Society of Chemistry 39 ) .

2.5. Liver-on-a-chip
The liver is located on the right side of the abdomen with two large sections, or lobes, at the right and the
left, as illustrated in Figure 12. 40 The lobule and the acinus are important functional units for the structural
organization of the human liver. 41 It performs more than 500 functions and many of them are very crucial to
sustaining life. Some of these functions can be summarized as removal of toxins (detoxifications), storing of
fat-soluble vitamins (A, D, E, and K), and regulation of blood glucose levels while synthesizing clotting factors.
It also has an important eﬀect on blood circulation and filtration and the release of bile, proteins, carbohydrate,
cholesterol, and so on. All of these important functions make the liver sensitive and vulnerable, especially to
adverse eﬀects of certain medications when overdosed and occasionally even at therapeutic ranges. For this
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reason, the liver has become a target of drug-induced toxicity and hepatotoxicity. Unfortunately, this also
makes the predictions of liver response challenging and hence it is very diﬃcult to mimic the liver in vitro.

Figure 12. General representation of the human liver and its parts (reprinted with permission from the editors of
Encyclopædia Britannica; copyright (2016), Encyclopædia Britannica 40 ) .

However, building microfluidic devices can still provide useful information for the responses of the human
liver when used in drug testing. A couple of researchers have cultured primary hepatocytes in microfluidic
devices to accelerate the drug development and screening process. Lee et al. demonstrated the potential use of
PDMS-made microfluidic channels for mimicking liver anatomy (Figure 13). 42 For the microfabrication process,
epoxy-based negative photoresist (SU-8) for silicone replicate molding with photo-lithography was used to form
fluid flow and cell-loading channels. In this study, a cell area was utilized for cell culturing and the medium moved
in the flow channel outside of the endothelial-like barrier, partially passing through the endothelial barrier to
the cells. Extensive cell–cell contact, continuous nutrient exchange, mimicking of the natural endothelial barrier
layer, and culturing of primary hepatocytes for over 7 days without decreasing viability were some important
features of the microdevice. On the other hand, the lack of experiments related to waste and toxicity is a
downside for the proposed design.

Figure 13. Photograph and schematic representation of in vitro microfluidic liver sinusoid with the endothelial barrier
layer (reprinted with permission from Lee et al.; copyright (2007), John Wiley & Sons 42 ) .

Various studies have also been conducted recently to obtain diﬀerent types of liver-on-chip microdevices
to investigate the potential adverse eﬀects of drugs and treatments. Bhushan and coworkers worked on 3D
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microfluidic constructs to mimic functional human liver tissue of the acinus and oxygen gradient that contains
four diﬀerent cell types of hepatocytes, stellate cells, Kupﬀer cells, and endothelial cells (Figure 14). 43 This chip
generates biochemical and metabolic information by the formation of coculturing with synthetic and enzymatic
stable functions in at least 4 weeks. Another key point of the model is that the bioengineered chip has fluorescent
markers, which can visually indicate changes in cell function when a toxic drug is added to investigate druginduced liver injury such as fibrotic scarring, cell damage from free radicals, liver failure, and so on. Using
such a device, a database, which is the collection of real-time monitoring of changes in cell function, cell death,
or damage after drug exposure (Figure 14), can be obtained with clinically relevant hepatotoxic in vivo drug
exposure to construct predictive models of human hepatotoxicity.

Figure 14. Schematic illustration of developing a liver-on-a-chip to mimic liver acinus: (A) acinus microchip model
includes four liver cell types with sentinel cells cultured in the device; (B) investigation of the microchip functions by
sentinel biosensors by quantitation readouts; (C) external sources supplied to database with analyzing of graphs and
outputs (reprinted with permission from Bhushan et al.; copyright (2013), BioMed Central 43 ) .

3. 3D bioprinting systems
One of the most important scientific advancements that may provide a high impact on organ-on-a-chip research
is the recent progress in 3D bioprinting technologies. Obviously, bioprinting is not the only method to
fabricate tissue models for organ-on-chip systems. To date, there have been many strategies employed to
fabricate functional tissues, such as 3D scaﬀolding, 44−47 microengineering based on self-assembly,... 48,49 fiber
engineering, 50 and scaﬀold-free cell sheet engineering, 51 among others. 52,53 Scaﬀolds, derived from materials
like biodegradable polymers, can be refined into desired architectures in 3D, thus allowing the seeded cells
to attach, proliferate, migrate, and diﬀerentiate. 44,47 Microscale building units such as DNA sequences have
the potential to self-assemble into bulk volumes of desired structures that present the properties of the target
tissues.... 49,54 Fiber engineering based on the cell-laden fibers may also be utilized as the structural units and
erected into stratified configurations through weaving, knitting, and spooling.... 50,55 Scaﬀold-free cell sheet
engineering depends on accumulating thin sheets of cells layer by layer to fabricate 3D tissue constructs. 51
Despite the fact that all of these strategies have several benefits, none of them have any potential to produce
volumetric tissue constructs at high spatial precision.
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3D bioprinting is a recently developed biofabrication strategy that is capable of constituting 3D tissue
constructs with unprecedented accuracy and remarkable precision in patterning biomaterials and cells in a
highly reproducible manner empowered by the programmed fabrication mechanisms.... 56−59
Until recently, a variety of bioprinting strategies have been formulated and fabricated, including those
based on stereolithography, inkjet, extrusion, and laser-assisted bioprinting; each comes with their own unique
advantages and disadvantages to engineer diﬀerent types of organ and tissue substitutes. In this section, the
most common techniques are outlined in order to emphasize the importance of 3D bioprinting strategies for
organ-on-a-chip research.
3.1. Stereolithography bioprinting
In 1986, Charles W Hull described stereolithography bioprinter as an additive manufacturing technique that
employs a printhead that can travel on the z-axis and a reservoir filled with cell-laden bioink, which can
be selectively solidified layer by layer by photo-polymerization. 60 Stereolithography was first used in medical
engineering to biomimic highly accurate and detailed models of the cranium in reconstructive head surgery. 61
In the basic concept of stereolithography bioprinting, 2D patterns are projected onto the bioink layer by
layer, resulting in the creation of complex structures without a moveable printhead in the x-y direction and
faster fabricating of structures when compared with other nozzle-based bioprinters. This process of photopolymerization prevents the eﬀect of shear stress on cells and allows bioprinted structures to achieve more than
85% high cell viability. Moreover, this technique does not require highly viscous bioinks and thus extends the
choice for biomaterials. 62 A schematic of the photo-polymerization system is shown in Figure 15. 63
3.2. Inkjet bioprinting
Inkjet bioprinting was invented in 2003 and patented in 2006. 64 An inkjet bioprinter is actually a 2D inkjet
printer, where a bioink is used instead of conventional ink and the paper is replaced with an x-y-z controllable
platform that allows for the 3D manufacturing of objects (Figure 16a). Bioink is transferred onto the platform
through an extruder that is controlled by thermal or piezoelectric actuation. This extrusion allows droplet-wise
formation of bioink on the platform and permits the construction of 2D bioprinted layers of desired structure
in the z direction. This erection eventually fabricates a 3D object. Simplicity and low cost appear as the
most forthcoming advantages of inkjet bioprinting. 60,63 In addition, in inkjet bioprinting, several printheads
can work together simultaneously and fabricate high resolution (∼30 µ m) structures rapidly. 60,62,64 Also,
inkjet bioprinting provides high cell viability ratios of more than 80%–90% in bioprinted structures. 62,65 Gao
et al. fabricated an inkjet bioprinter that has the capability to deposit eight materials simultaneously and
crosslink the bioprinted structures. 66 This inkjet bioprinter was used to fabricate mechanically strong bone and
cartilage constructs using poly(ethylene glycol)dimethacrylate (PEGDMA), GelMA, and encapsulated human
mesenchymal stem cells. Moreover, Chang et al. fabricated an inkjet bioprinter that successfully bioprinted
bifurcated vascular structures. 67
3.3. Extrusion-based bioprinting
In 2002, Zein et al. developed the basic principles of extrusion-based 3D bioprinting for tissue engineering for
the first time. 68 Poly(ε-caprolactone) (PCL) scaﬀolds are fabricated through an extrusion-based design with
a heating system for extruding the heated and melted material. Pneumatic and mechanical-driven extrusionbased bioprinters appear as the most common versions in the market due to their high performance in tissue
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Figure 15. Schematic of the system. An aluminum frame is used to support the custom precision translation stages and
projector system. Light from a UV laser and a red LED are combined using a Y-fiber, which is then used to illuminate a
Digital Micromirror Device (DMD) projector. A lens is used to project the image of the DMD onto a sample slide, which
is immersed in the photopolymer (reprinted with permission from Lee et al.; copyright (2015), Macmillan Publishers
Limited 63 ) .

Figure 16. Three most common 3D bioprinting techniques: (a) inkjet bioprinters, (b) microextrusion bioprinters, and
(c) laser-assisted bioprinter (reprinted with permission from Malda et al.; copyright (2013), John Wiley & Sons 56 ) .

engineering (Figure 16b). Pneumatic systems that enable high resolution bioprinting are mainly controlled
by valve mechanisms. 69 They provide serious advantages with control over pressure and pulse frequencies.
Almost all of the mechanical systems are controlled by a piston or by a screw. Screw-driven systems are mainly
preferred for inks with higher viscosities due to higher spatial control. However, it is known that nozzle exits
of the screw-driven systems may harm cells because of the high pressure that is applied to them. 69,70 When
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extrusion-based bioprinting is compared with other aforementioned platforms, it is obvious that this technique
possesses serious advantages, such as the capability of printing highly viscous bioinks (30 MPa s to >6 × 10 7
MPa s) in high cell densities. 62,67,71 Moreover, it should be noted that extrusion-based bioprinting systems have
the capacity to extrude bioinks continuously without any interruptions. This is preferred in many applications
since the integrity of bioprinted tissue constructs is one of the most important problems to be considered.
Therefore, since the invention of extrusion-based bioprinting, this technique has appeared as one of the most
widely adopted forms of bioprinting due to its high capability of constructing integrated structures.
3.4. Laser-induced forward transfer bioprinting
Laser-induced forward transfer (LIFT) bioprinting is also known as laser-assisted or laser direct-write bioprinting. 72,73 In 2007, Duocastella et al. published the first paper based on laser-assisted bioprinting and proved
the potential of this method for biomedical applications. 74 LIFT bioprinting systems mainly consist of three
layers: a donor layer, an energy-absorbing layer, and a layer of bioink (Figure 16c). The donor layer responds
to an applied laser beam and this makes it the most crucial part of the system. An energy-absorbing layer such
as titanium or gold is attached on top of this donor layer, and at the bottom of the donor layer a thin layer of
bioink is suspended. Corresponding locations of the donor layer are vaporized at the moment a selective laser
beam is applied to the designed parts of the energy-absorbing layer and thus creates a high-pressure bubble
at the interface. This pressure drives bioink in droplet formations onto the collection platforms. Eventually
a 3D construct is fabricated by controlling the z stage of the collector. In LIFT bioprinting, the cells are
not exposed to high shear stress since there are no contacts between the dispenser and the bioink, resulting
in the highest cell viability ratio (> 95%) when compared with other aforementioned bioprinting techniques.
In addition, this advantage enables LIFT bioprinting to print structures with highly viscous materials (1–300
MPa s). 62,67 By using LIFT, Ali et al. successfully printed mesenchymal stem cells in high resolution with high
viability. 75 Recently, Guillemot et al. invented and Guillotin et al. improved LIFT technology and invented a
high-throughput laser printing system that successfully achieved a very high cell-level resolution (10 µ m) at a
very high speed of printing (5 kHz). 76,77 Today, LIFT presents high potential printing capability based on the
contactless printing with high speed.
4. Conclusion and future perspectives
The design, development, and then testing of a new drug or treatment is a lengthy process associated with
tremendous costs and high failure rates. Traditional approaches like 2D models for monitoring and measuring
the eﬀects of the drug on the molecular basis of a disease have many limitations that arise from the more
sophisticated nature of real biological systems. 78 As a result of technological advances in the field, the concept
of organs-on-chips has been developed, which is expected to mimic specialized organ and immune system
responses, reveal correlations between a drug and its toxic eﬀects with lower reagent consumption, and provide
better ability to resemble cellular microenvironments. 78−82 In a short period of time, many studies have been
carried out to simulate the liver, blood vessels, brain, skin, and so on using microengineered platforms so
that at least the minimal functional units of living organs can be artificially modeled and potentially used for
biomedical, pharmaceutical, and environmental safety testing applications. Even if there is a need for more
multidisciplinary approaches to achieve their full potential before the models become packaged test solutions
acceptable to the pharmaceutical industry, there are several important advantages of these models. These can
be summarized as:
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• Relatively smaller 3D experimental setups with the capability of controlling the positions of cells and
tissue–tissue interfaces, transcellular molecules, and their concentration gradient will be advantageous to
analyze new drugs-on-chips systems to obtain more accurate results than animal models. 83
• Organ-on-a-chip systems will potentially replace animal testing, or at least reduce it, thus eliminating the
ethical issues often raised by animal rights groups.
• Achievements in the organ-on-a-chip field can reduce the amount of testing determined before and during
clinical trials in human patients. 84
• Combination of gene-replacement technology with the stem cells from an individual patient might lead to
personalized medicine or treatment and disease models. 78,85
On the other hand, the ultimate goal is clearly to develop in vitro model systems of human-on-a-chip that
imitate more complex tissue constructs using diﬀerent types of novel biocompatible materials. However, more
sophisticated microsystems are still needed in order to incorporate multiple tissues and vascular channels on a
single microdevice since the ultimate goal is to transform fundamental human cells or induced pluripotent stem
cells into mature cells while controlling or preventing long-term diﬀerentiation to simulate in vivo cell activities
precisely. 5,86,87 Almost all microorgan models do not contain enough variety of cells like the mimicked actual
organ has, but rather just focus on a single property of cells or cell behaviors, like fusion, ECM–cell interaction,
and cell–cell interaction. 88−92 Another issue with the current models is the lack of an intermediate structure
or form like the absence of fibroblasts between the endothelial and epithelial tissue of lung-on-a-chip models
maintaining the organ-specific cells by proliferation and diﬀerentiation capacity.
Organ-on-a-chip systems are still a relatively new area for research and are not yet explored in detail in
some biomedical fields such as chronic disease and complicated reactions in the endocrine system or skeletal and
nervous systems due to limited working time (i.e. less than a month). For consistent reliability, they should
maintain structural integrity after long-term exposure to drugs and biological solutions.
To construct organ-on-a-chip systems, PDMS is widely used currently, but for long-term stability, reliability, better chemical resistance, biocompatibility, reduced absorbance of small hydrophobic molecules on its
surface, and solvent eﬀects that seriously aﬀect drug eﬃcacy and toxicity, it should be improved or replaced with
new materials. 87,93 Another major drawback of PDMS is the production of membranes that are considerably
thicker when compared with real in vivo forms. Based on many experiments, structural integrity is destroyed
when the flexible and porous PDMS membrane is produced thinner than 10 µ m. 86 Various attempts have been
made to find a more suitable alternative material instead of PDMS; however, there is no satisfactory substitute
that can potentially replace PDMS-made devices. 80,93
In order to improve our understanding of specific metabolic and cell–cell interactions with the eﬀect
of applying drugs on organ-on-a-chip models, we need mathematical, physical, and simulation models with
acceptable accuracy and analysis of complex flows in the cell media. For controllability and long-term usage,
automation of organ-on-a-chip systems, monitoring, and data collection points and times need to be standardized
and optimized after developing a consensus at least among engineers, pharmacists, and medical doctors.
Customized sensors with regeneration capacity and high sensitivity to detect trace changes (<1 ng mL −1 or
only the target molecule or biomarker in the complex medium) and longer shelf life are also highly demanded. 94
Alternatively, 3D bioprinting enables us to perform rapid fabrication of organs and tissues in threedimensional biomimetic structures for applications in tissue engineering and regenerative medicine that may
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possibly be associated with organ-on-a-chip systems. It is obvious that in such a case the synergy created by
this association will lead to significant advancement for organ-on-a-chip research. However, there are still many
challenges on the path towards the development of more viable 3D bioprinting technologies. Unfortunately,
none of the tissues and organs are composed of one single cell type. For instance, pacemaker cells lying in
the Purkinje fibers initiate the contraction of the heart’s chambers and this should be considered when heart
tissue is needed for heart-on-a-chip research. 95−97 For liver-on-a chip research, researchers should be aware that
hepatocytes are the most crucial elements for liver functions but other nonparenchymal cells like Kupﬀer cells,
hepatic stellate cells, and biliary epithelial cells are also of vital importance. 58,95,98
In addition, vascularization is another critical component for every living tissue. Perfusable endothelial
tubes that have capability to transport nutrients and oxygen among diﬀerent sections of organs and tissues, and
to remove metabolic wastes such as acids and carbon dioxide to maintain the homeostasis of the human body,
should be embedded within all fabricated tissue constructs. 99,100 Fabricated tissues and organs have no chance
to survive on their own without an interconnected vascular network.
With further development and optimization towards multiplexing organs-on-chips to form human-on-achip models, it is highly expected that these systems will find widespread applications in monitoring the eﬀects
of drug exposure even at trace amounts and in situ treatments could potentially serve as a replacement for
traditional in vivo models.
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56. Malda, J.; Visser, J.; Melchels, F. P.; Jüngst, T.; Hennink, W. E.; Dhert, W. J.; Groll, J.; Hutmacher, D. W. Adv.
Mater. 2013, 25, 5011-5028.
57. Li, Y. C.; Zhang, Y. S.; Akpek, A.; Shin, S. R.; Khademhosseini, A. Biofabrication 2016, 9, 012001.
58. Zhang, Y. S.; Yue, K.; Aleman, J.; Mollazadeh-Moghaddam, K.; Bakht, S. M.; Yang, J.; Jia, W.; Dell’Erba, V.;
Assawes, P.; Shin, S. R. et al. Ann. Biomed. Eng. 2017, 45, 148-163.
59. Murphy, S. V.; Atala, A. Nat. Biotechnol. 2014, 32, 773-785.
60. Hull, C. W. U.S. Patent No. 4,575,330 ; US Patent Oﬃce: Washington, DC, USA, 1986.
61. Klimek, L.; Klein, H. M.; Schneider, W.; Mösges, R.; Schmelzer, B.; Voy, E. D. Acta Otorhinolaryngo. Belg. 1992,
47, 329-334.
62. Mandrycky, C.; Wang, Z.; Kim, K.; Kim, D. H. Biotechnol. Adv. 2016, 34, 422-434.
63. Lee, M. P.; Cooper, G. J.; Hinkley, T.; Gibson, G. M.; Padgett, M. J.; Cronin, L. Sci. Rep. 2015, 5, 9875.
64. Boland, T.; Wilson, W. C.; Xu, T. U.S. Patent No 7051654 B2 ; US Patent Oﬃce: Washington, DC, USA, 2003.
65. Wilson, W. C.; Boland, T. Anat. Rec. Part A 2003, 272, 491-496.
66. Gao, G.; Schilling, A. F.; Hubbell, K.; Yonezawa, T.; Truong, D.; Hong, Y.; Dai, G.; Cui, X. Biotechnol. Lett. 2015,
37, 2349-2355.
67. Chang, C. C.; Boland, E. D.; Williams, S. K.; Hoying, J. B. J. Biomed. Mater. Res. B 2011, 98, 160-170.
68. Zein, I.; Hutmacher, D. W.; Tan, K. C.; Teoh, S. H. Biomaterials 2002, 23, 1169-1185.
69. Ozbolat, I. T.; Hospodiuk, M. Biomaterials 2016, 76, 321-343.
70. Fielding, G. A.; Bandyopadhyay, A.; Bose, S. Dent. Mater. 2012, 28, 113-122.
71. Murphy, S. V.; Skardal, A.; Atala, A. J. Biomed. Mater. Res. A 2013, 101, 272-284.
72. Bohandy, J.; Kim, B. F.; Adrian, F. J. J. Appl. Phys. 1986, 60, 1538-1539.
73. Kattamis, N. T.; Purnick, P. E.; Weiss, R.; Arnold, C. B. Appl. Phys. Lett. 2007, 91, 171120.
74. Duocastella, M.; Colina, M.; Fernández-Pradas, J. M.; Serra, P.; Morenza, J. L. Applied Surf. Sci. 2007, 253,
7855-7859.
75. Ali, M.; Pages, E.; Ducom, A.; Fontaine, A.; Guillemot, F. Biofabrication 2014, 6, 045001.
76. Guillemot, F.; Souquet, A.; Catros, S.; Guillotin, B.; Lopez, J.; Faucon, M.; Pippenger, B.; Bareille, R.; Rémy, M.;
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Bordenave, L.; Amédée, J. et al. Biomaterials 2010, 31, 7250-7256.
78. Bhatia, S. N.; Ingber, D. E. Nat. Biotechnol. 2014, 32, 760-772.
79. Huh, D.; Torisawa, Y.; Hamilton, G. A.; Kim, H. J.; Ingber, D. E. Lab Chip 2012, 12, 2156-2164.

609

AVCI et al./Turk J Chem

80. Esch, M. B.; Sung, J. H.; Shuler, M. L. J. Biotechnol. 2010, 148, 64-69.
81. Shin, S. R.; Kilic, T.; Zhang, Y. S.; Avci, H.; Hu, N.; Kim, D., Branco, C.; Aleman, J.; Massa, S.; Silvestri, A. et
al. Adv. Sci. 2017, 4, 1-14.
82. Zhang, Y. S.; Aleman, J.; Shin, S. R.; Kilic, T.; Kim, D.; Shaegh, S. A. M.; Massa, S., Riahi, R.; Chae, S.; Hu, N.
et al. P. Natl. Acad. Sci. USA 2017, 114, E2293-E2302.
83. Kim, S.; Takayama, S. Kidney Res. Clin. Pract. 2015, 34, 165-169.
84. Esch, E. W.; Bahinski, A.; Huh, D. Nat. Rev. Drug Discov. 2015, 14, 248-260.
85. Wang, G.; McCain, M. L.; Yang, L.; He, A.; Pasqualini, F. S.; Agarwal, A.; Yuan, H.; Jiang, D.; Zhang, D.; Zangi,
L. et al. Nat. Med. 2014, 20, 616-623.
86. Huh, D.; Kim, H. J.; Fraser, J. P.; Shea, D. E.; Khan, M.; Bahinski, A.; Hamilton, G. A.; Ingber, D. E. Nat. Protoc.
2013, 8, 2135-2157.
87. Huh, D.; Hamilton, G. A.; Ingber, D. E. Trends Cell Biol. 2011, 21, 745-754.
88. Yang, X.; Mironov, V.; Wang, Q. J. Theor. Biol. 2012, 303, 110-118.
89. Yang, X., Sun, Y., Wang, Q. J. Biomech. Eng. 2013, 135, 71005.
90. Thomas, G. L.; Mironov, V.; Nagy-Mehez, A.; Mombach, J. C. M. Physica A 2014, 395, 247-254.
91. Ki, C. S.; Lin, T. Y.; Korc, M.; Lin, C. C. Biomaterials 2014, 35, 9668-9677.
92. Abdulla, T.; Imms, R. A.; Schleich, J. M.; Summers, R. In Proceedings of the 33rd Annual International Conference
of the IEEE EMBS, Boston, MA, USA, 30 August–3 September 2011, pp. 449-452.
93. Sackmann, E. K.; Fulton, A. L.; Beebe, D. J. Nature 2014, 507, 181-189.
94. Shin, S.; Zhang, Y. S.; Kim, D.; Manbohi, A.; Avci, H.; Silvestri, A.; Aleman, J.; Hu, N.; Kilic, T.; Keung, W. et
al. Anal. Chem. 2016, 88, 10019-10027.
95. Saladin, K. S.; Miller L. Anatomy & Physiology: The Unity of Form and Function;
NY, USA, 1998.

McGraw-Hill: New York,

96. Zhang, Y. S.; Aleman, J.; Arneri, A.; Bersini, S.; Piraino, F.; Shin, S. R.; Dokmeci, M. R.; Khademhosseini, A.
Biomed. Mater. 2015, 10, 034006.
97. Tomanek, R. J.;. Runyan, R. B., Eds. Formation of the Heart and Its Regulation; Birkhäuser: Boston, MA, USA,
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